The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
“There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections. Evizon is differentiated from other competitor drugs having demonstrated a positive effect in both study and fellow affected eyes in previous clinical trials,” said Jack Armstrong, president and CEO.
Genaera Corporation is developing medicines to address substantial unmet medical needs in major pharmaceutical markets. The company has products in development for the treatment of eye disorders, cancer, respiratory disorders and metabolic syndrome. Evizon is Genaera's lead product in development for ophthalmic indications, specifically wet AMD.